Press Releases

There are currently no events to display.
Date Title  
09/03/20
Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 3, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc. , and a global leader in the development, manufacture and commercialization of innovative
08/12/20
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 12, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc. , and a global leader in the development, manufacture and commercialization of innovative
07/30/20
Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results
Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline Worldwide revenue of $66.0 million for the second quarter 2020, representing a decrease of 23.0% from the prior year period Net loss of $7.0 million for the second
07/23/20
Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 23, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 30, 2020 , to discuss its financial and operating results for the second quarter of 2020.
07/01/20
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 1, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative
06/22/20
Lantheus Completes Merger with Progenics
NORTH BILLERICA, Mass. & NEW YORK --(BUSINESS WIRE)--Jun. 22, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents
06/16/20
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 16, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced
06/16/20
Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 16, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products,
05/20/20
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--May 20, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products,
05/18/20
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third Quarter 2020 - NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
05/05/20
Lantheus Holdings to Present at the UBS Virtual Global Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--May 5, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products,
04/30/20
Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results
Worldwide revenue of $90.7 million for the first quarter 2020, representing an increase of 4.8% over the prior year period Net income of $3.3 million for the first quarter 2020, representing a decrease of 66.5% from the prior year period GAAP diluted EPS of $0.08 for the first quarter 2020,
04/16/20
Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, April 30, 2020 , to discuss its financial and operating results for the first quarter of 2020.
04/14/20
Velan Capital Agrees to Support Merger of Lantheus and Progenics
NORTH BILLERICA, Mass. & NEW YORK --(BUSINESS WIRE)--Apr. 14, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products,
04/09/20
Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 9, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced
04/06/20
Lantheus Holdings, Inc. to Hold 2020 Annual Meeting of Stockholders Virtually
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 6, 2020-- In response to continued public health concerns about in-person gatherings given the coronavirus/COVID-19 outbreak, the Board of Directors of Lantheus Holding, Inc. (the “Company”) (NASDAQ:LNTH) has determined to change the format of the
04/02/20
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 2, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics
02/25/20
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
Worldwide revenue of $89.3 million and $347.3 million for the fourth quarter and full year 2019, representing an increase of 3.6% and 1.2% over the prior year period, respectively Net income of $10.5 million and $31.7 million for the fourth quarter and full year 2019, representing a decrease of
02/20/20
Lantheus and Progenics Agree to Amended Transaction Terms
Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combined Company
02/18/20
Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products,
02/18/20
Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020 , to discuss its financial and operating results for the fourth quarter and full year of
02/03/20
Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 3, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and
01/27/20
Lantheus Holdings Announces Senior Leadership Appointment
Company Appoints Paul Blanchfield as Chief Commercial Officer NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 27, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of
01/13/20
Lantheus Holdings Announces Senior Leadership Appointment
Company Appoints Istvan Molnar, M.D. as Chief Medical Officer NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 13, 2020-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of